Cph Group Ag Class A · SIX:CPHN
Cph Group Ag Class A — Investor Day (September 2025)
40 slides from Cph Group Ag Class A's investor day presentation, Sep 16, 2025
Slide 1: CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals
CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals Focused. Leading. Innovative. Investors’ Day, Zurich, 16 September 2025
Slide 2: Disclaimer
Disclaimer Investing in the shares of CPH Group AG involves risks. Prospective investors are urged to consult their investment advisors and tax advisors prior to investing in CPH Group AG shares. This document contains forward-looking statements which involve risks and uncertainties. These statement
Slide 3: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 4: CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals
CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals 1. Strong market positioning: Globally among the Top 3 in attractive niche markets 2. Growth driven by megatrends: Health & demography and energy 3. Growth by international expansion: Organic expansion with foc
Slide 5: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 6: Leading market positions in growth markets
Leading market positions in growth markets Group Strategic and financial management with focus on - Innovation and product development - Growth in attractive niche markets - Operational excellence Division Perlen Packaging Zeochem Market position Worldwide amongst Top 3 for coated Worldwide amongst
Slide 7: Business locations worldwide
Business locations worldwide Consistent and ongoing internationalization Müllheim Tököl 2007 2024 Québec 2025 Zvornik Paris 2018 2025 Ashdot Donghai Ya’akov Ihud 2016 Whippany 2024 Suzhou Louisville 2006 2016 1979 Perlen Rüti* Shanghai 1954 2018 2015 Vadodara 2024 Singapore 2009 Anápolis 2018 *Found
Slide 8: Growth drivers supported by global megatrends
Growth drivers supported by global megatrends Megatrends Markets Applications Products Division Medicines Pharmaceutical packaging Respirators Molecular sieves Health & Demography Pharmaceuticals Medical oxygen Chromatography gels API Deuterated products Fahrzeug- komponenten Erdgas Natural gas/LNG
Slide 9: Value drivers and success factors
Value drivers and success factors Growth driver / Megatrends • Health & Demography • Energy Strategic roadmap Leading market positions • Innovation and product development • Top 3 positions in attractive niche markets • Organic growth • Global presence • Potential for non-organic growth • Focus on g
Slide 10: Key figures CPH Group
Key figures CPH Group 75% of sales from health market Sales1 EBITDA and EBITDA margin1 Market capitalisation as of 11.09.2025 In CHF million In CHF million / % of sales in CHF million 400 70 25% CAGR 8.2% CAGR 9.3% 350 60 444 300 20% 50 250 40 15% 200 150 30 10% 100 20 10 5% 50 0 0 0% 6 000 000 Ordi
Slide 11: Experienced and well-rehearsed management team
Experienced and well-rehearsed management team Alois Waldburg-Zeil Gerold Brütsch Marc Haller Group CEO (since 2025) & Group CFO (since 2022) Head of Packaging (since 2022) Head of Chemistry (since 2010) Experience: Approx. 30 years in the Experience: More than 35 years in Experience: More than 25 y
Slide 12: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 13: Perlen Packaging – a true global player
Perlen Packaging – a true global player Unique position in pharmaceutical packaging Key figures 2024 (in CHF million) • Sales 206 5yrs CAGR 6.1% Müllheim • EBITDA 33 EBITDA margin 16.1% 2007 Tököl 2025 Ashdot Employees Ya’akov Ihud Suzhou 2016 Perlen 2025 Whippany • 8131 2006 1954 Global presence cl
Slide 14: Perlen Packaging: Pharmaceutical packaging with best protection for medicines
Perlen Packaging Pharmaceutical packaging with best protection for medicines Barrier effect Films for tablet blisters Up to 2x better* 50x Effectiveness of better* water vapour barrier Effectiveness of oxygen barrier 100x 100x Up to 4x Bottles and containers Up to 4x better* better* better* better*
Slide 15: Perlen Packaging: No. 1 worldwide in highest barrier blister
Perlen Packaging No. 1 worldwide in highest barrier blister1 Global pharmaceutical market The largest markets Global pharmaceutical blister market: CHF 2 billion1 Strategic directions - Outlook 20262 Growth: 3-6% p.a.2 Leverage LOG 1: USA Leading suppliers in the plastic blister segment: Pharma’s fu
Slide 16: Perlen Packaging Key figures
Perlen Packaging Key figures Sales EBITDA and EBITDA margin Key take aways In CHF million / in % In CHF million / % of sales 250 45 25% CAGR 6.1% CAGR 4.6% 100% pharmaceutical market 200 20% 30 150 15% Above market growth rates 100 10% 15 50 5% Covid-related destocking effect in 2024 0 0 0% 2020 202
Slide 17: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 18: Zeochem – top global niche player in specialty chemicals
Zeochem – top global niche player in specialty chemicals Leading market position backed by global megatrends Key figures 2024 (in CHF million) • Sales 117 5yrs CAGR 12.5% Paris • EBITDA 23 EBITDA margin 19.5% 2025 Zvornik 2018 Donghai 2016 Employees Louisville Québec Rüti* 2018 Shanghai 1979 2025 20
Slide 19: Zeochem: Product portfolio improves quality of life and enables energy transition
Zeochem Product portfolio improves quality of life and enables energy transition Molecular sieves Molecular sieves are used in removing unwanted molecules and in purifying gas such as natural and industrial gases, liquides such as ethanol and in enabling oxygen production for life-saving oxygen ther
Slide 20: Zeochem: Molecular sieves for industrial applications
Zeochem Molecular sieves for industrial applications Market overview Industries Strategic directions Global fragmented market • Pharmaceuticals Accelerated with growth 2-3%1 p.a. • Electronics development of Segment molecular sieves: • Petrochemistry market in India CHF 500-700 million1 through • Ma
Slide 21: Zeochem: Chromatography gels for pharmaceuticals
Zeochem Chromatography gels for pharmaceuticals Market overview Industries Strategic directions Global fragmented market • Pharmaceuticals Develop potential with growth 5-10%1 p.a. • Biopharmaceuticals of high performing Segment chromatography gels: • Academia & Universities products of CHF 150-250
Slide 22: Zeochem: Deuterated products for pharmaceuticals and electronics
Zeochem Deuterated products for pharmaceuticals and electronics Market overview Industries Strategic directions Global fragmented market • Pharmaceuticals Focus on with growth 10%1 p.a. • Electronics innovation Segment deuterated products: • Basic research Increased CHF 100-150 million1 production c
Slide 23: Zeochem Key figures
Zeochem Key figures Sales EBITDA and EBITDA margin Key take aways In CHF million In CHF million / % of sales 140 25 25% CAGR 12.5% CAGR 24.6% Above market growth with strong 120 20 20% 100 increase in profitability 80 15 15% 60 10 10% 71% of sales in attractive health 40 and energy markets 20 5 5% 0
Slide 24: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 25: Half-year 2025 Consolidated income statement I
Half-year 2025 Consolidated income statement I 01.01.-30.06., in CHF millions1 2025 % 2024 % ± ±% Net sales 1 176.0 100.0 176.9 100.0 -0.9 -0.5% 1 Net sales 0.5% below prior-year period, thereof -3.5% due to FX and +8.2% from Other operating income 1.8 1.0 1.4 0.8 acquisitions; organic decline in pa
Slide 26: Half-year 2025 Consolidated income statement II
Half-year 2025 Consolidated income statement II 01.01.-30.06., in CHF millions1 2025 % 2024 % ± ±% EBITDA 30.2 17.2 30.2 17.1 - +0.1% 1 Depreciation and amortization above prior-year period as a consequence of the Sorbchem and Depreciation and amortization 1 -8.3 -4.7 -6.7 -3.8 LOG Pharma acquisitio
Slide 27: Half-year 2025 Consolidated balance sheet
Half-year 2025 Consolidated balance sheet in CHF millions 30.06.2025 % 31.12.2024 % ± ±% Cash and cash equivalents 25.6 7.0 31.6 9.5 1 Increase in total assets and capital employed by CHF 32 million from LOG Pharma acquisition Trade receivables 67.4 18.5 48.3 14.5 2 Financial liabilities increased b
Slide 28: Half-year 2025 Consolidated cash flow statement
Half-year 2025 Consolidated cash flow statement 01.01.-30.06., in CHF millions 2 2025 % 2024 % ± ±% Net result 17.1 9.7 21.1 11.9 -4.0 -19.0% 1 Temporary seasonal increase in net working capital Non-cash items 8.4 4.8 6.1 3.5 2 Cash flow from investing activities include Cash flow 25.5 14.5 27.2 15.
Slide 29: Segment results for the first-half of 2025
Segment results for the first-half of 2025 Perlen Packaging Zeochem CPH Group 1 01.01.-30.06., in CHF millions 2025 2024 ±% 2025 2024 ±% 2025 2024 ±% Sales 118.4 114.9 +3.1% 57.5 62.0 -7.2% 176.0 176.9 -0.5% EBITDA 17.8 20.4 -12.6% 12.2 10.4 +17.4% 30.2 30.2 +0.1% EBITDA margin 15.0% 17.8% 21.2% 16.
Slide 30: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 31: A comprehensive strategy to achieve attractive financial targets
A comprehensive strategy to achieve attractive financial targets Among the top 3 in attractive niche markets with above average growth potential Positioning in the global megatrends health & demography and energy Expansion of market position with a focus on growth regions and emerging markets outsid
Slide 32: A comprehensive set of growth initiatives supports future development
A comprehensive set of growth initiatives supports future development Sales push Strengthening of sales organizations in attractive niche markets Innovation Widening of product portfolio with constant customer focus Capacity utilization Increase capacity utilization worldwide India Grow market share
Slide 33: Strategic capital allocation
Strategic capital allocation M&A and partnerships as strategic enabler Objectives • Augment organic growth and create sustainable shareholder value Guiding principles • Strategic fit: Aligns with core markets in pharmaceutical packaging and specialty chemistry expanding market coverage and product o
Slide 34: Sustainable corporate management
Sustainable corporate management Sustainable value creation • Long-term corporate purpose embedded; assessment of ESG-driven market opportunities Net-zero strategy • Striving for net zero; preparing an appropriate stage plan, while maintaining competitiveness (92% of emissions from upstream and down
Slide 35: Mid-term targets
Mid-term targets Continuing growth and attractive margins Growth Profitability Sales increase EBITDA margins 5-8% p.a. 16-18% Cash flow Financing Dividend Free cash Equity ratio Payout ratio flow margins 8-10% >50% 25-50% CPH Group Investors’ Day in Zurich, 16 September 2025 35
Slide 36: Agenda
Agenda 1. Investment Highlights Alois Waldburg-Zeil 2. Business Overview Alois Waldburg-Zeil 3. Market Insights Alois Waldburg-Zeil - Perlen Packaging - Zeochem 4. Financial Performance Gerold Brütsch 5. Strategy and Growth Targets Alois Waldburg-Zeil 6. Outlook and Summary Alois Waldburg-Zeil CPH G
Slide 37: Outlook 2025
Outlook 2025 CPH Group • Confident outlook • Conditions remain volatile • Earnings and net result expected above 2024 Perlen Packaging Zeochem • Sales above 2024, EBITDA broadly in line • Sales below and EBITDA above 2024 with previous year • Integration of Sorbchem India & SiliCycle CPH Group Inves
Slide 38: CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals
CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals 1. Potential for value increase by focusing on continued organic growth, combined with targeted acquisitions 2. Leading market position in the relevant markets with established brands 3. Consistent implementati
Slide 39: Calendar, analysts and contacts
Calendar, analysts and contacts Calendar 17.09.2025 Investora equity conference, Zurich 22.09.2025 Baader Investment Conference, Munich 14.-16.01.2026 Baader Helvea Swiss Equities Conference, Bad Ragaz 18.02.2026 Media and investors‘ conference, Publication of 2025 annual report 17.03.2026 Annual Ge
Slide 40: CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals
CPH Group, a global industrial leader in pharmaceutical packaging and specialty chemicals Focused. Leading. Innovative. CPH Group Investors’ Day in Zurich, 16 September 2025 40